Discovery, Optimization, and Biological Evaluation of Novel Pyrazol-5-yl-phenoxybenzamide Derivatives as Potent Succinate Dehydrogenase Inhibitors

The diphenyl ether molecular pharmacophore has played a significant role in the development of fungicidal compounds. In this study, a variety of pyrazol-5-yl-phenoxybenzamide derivatives were synthesized and evaluated for their potential to act as Succinate Dehydrogenase inhibitors (SDHIs). The bioassay results indicate certain compounds to display a remarkable and broad-spectrum in their Antifungal activities. Notably, compound 12x exhibited significant in vitro activities against Valsa mali, Gaeumannomyces graminis, and Botrytis cinerea, with EC₅₀ values of 0.52, 1.46, and 3.42 mg/L, respectively. These values were lower or comparable to those of Fluxapyroxad (EC₅₀ = 12.5, 1.93, and 8.33 mg/L, respectively). Additionally, compound 12x showed promising Antifungal activities against Sclerotinia sclerotiorum (EC₅₀ = 0.82 mg/L) and Rhizoctonia solani (EC₅₀ = 1.86 mg/L), albeit lower than Fluxapyroxad (EC₅₀ = 0.23 and 0.62 mg/L). Further in vivo experiments demonstrated compound 12x to possess effective protective Antifungal activities against V. mali and S. sclerotiorum at a concentration of 100 mg/L, with inhibition rates of 66.7 and 89.3%, respectively. In comparison, Fluxapyroxad showed inhibition rates of 29.2 and 96.4% against V. mali and S. sclerotiorum, respectively. Molecular docking analysis revealed that compound 12x interacts with SDH through hydrogen bonding, π-cation, and π-π interactions, providing insights into the probable mechanism of action. Furthermore, compound 12x exhibited greater binding energy and SDH Enzyme inhibitory activity than Fluxapyroxad (ΔGcal = -46.8 kcal/mol, IC₅₀ = 1.22 mg/L, compared to ΔGcal = -41.1 kcal/mol, IC₅₀ = 8.32 mg/L). Collectively, our results suggest that compound 12x could serve as a promising fungicidal lead compound for the development of more potent SDHIs for crop protection.

antifungal activity; diphenyl ether; molecular docking; pyrazole; structure–activity relationships.